Patent Cases – An Open Door for MOT Patent Litigation
Publication | 01.12.22
Expanded grounds for infringement could give branded drug companies an edge
A recent Federal Circuit ruling has opened what had been considered a closed door for litigation over pharmaceutical method-of-treatment (MOT) patents brought under the Hatch-Waxman Act. While the ruling’s implications differ for branded pharmaceutical makers and generic producers, one thing seems likely: MOT litigation is poised to take off.
How did we reach this point? As is typical with litigation, it goes back a few years and requires some explaining.
Read the complete article in the Litigation Forecast 2022.
Contacts
Insights
Publication | May 25-27, 2008
“ISI mitigation using bit-edge equalization in high-speed backplane data transmission,” in IEEE International Conference on Communications, Circuits and Systems (ICCCAS 2008), pp. 589 - 593.
Publication | 04.15.24
Publication | 04.10.24
Publication | 2023
